Table of contents  by unknown
991 Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-
case experience
Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo Nishimura, MD,
Ryutaro Kakinuma, MD, Hironobu Ohmatsu, MD, and Yutaka Nishiwaki, MD, Kashiwa, Japan
Computed tomography identifies pulmonary ground-glass opacity lesions not detected in
conventional radiographs. In a limited resection trial of these lesions, intraoperative
determination of Noguchi adenocarcinoma classification by frozen-section examination was
accurate. Limited resection for Noguchi types A and B in selected patients appears to be an
appropriate alternative to lobectomy.
997 Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in
general thoracic surgery: Evidence from randomized clinical trials
Artyom Sedrakyan, MD, PhD, Tom Treasure, MD, FRCS, John Browne, PhD,
Harlan Krumholz, MD, FACC, Carlos Sharpin, MSc, and Jan van der Meulen, PhD, London,
United Kingdom, and New Haven, Conn
A meta-analysis of 11 trials of antiarrhythmic medications that enrolled 1294 general thoracic
surgical patients was performed. Calcium-channel blockers and -blockers reduced the risk of
atrial tachyarrhythmia (RR of 0.50 and 95 CI of 0.34-0.73; RR of 0.40 and 95 CI of 0.17-0.95,
respectively). However, -blockers tended to increase the risk of pulmonary edema. Magnesium
tested in only one unblinded trial was also found to be useful. Digitalis was harmful and
increased the risk of atrial tachycardia. The efficacy and safety of amiodarone and flecainide
was associated with uncertainty.
1006 Laryngotracheoplastic resection for primary tumors of the proximal airway
Henning A. Gaissert, MD, Hermes C. Grillo, MD, Behgam M. Shadmehr, MD,
Cameron D. Wright, MD, Manjusha Gokhale, MA, John C. Wain, MD, and
Douglas J. Mathisen, MD, Boston and Brookline, Mass
Laryngotracheal resection of 25 primary airway tumors was performed by immediate
reconstruction with vascularized trachea. During a mean follow-up of 101 months, no patient
underwent laryngectomy for recurrence.
1010 The selective epidermal growth factor receptor tyrosine kinase inhibitor
PD153035 suppresses expression of prometastasis phenotypes in malignant
pleural mesothelioma cells in vitro
George W. Cole, Jr, MD, Annette M. Alleva, MD, Rishindra M. Reddy, MD,
Justin B. Maxhimer, BA, JingTong Zuo, MD, David S. Schrump, MD, FACS, and
Dao M. Nguyen, MD, FRCSC, FACS, Bethesda, Md
Targeting epidermal growth factor receptor (EGFR) by PD153035 significantly suppresses
clonogenic activity, cell motility, and Matrigel invasion of cultured malignant pleural
mesothelioma cells, regardless of their baseline EGFR expression. Inhibition of vascular
epidermal growth factor production, however, was only effective in EGFR-overexpressing cell
lines.
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